Page 98 - 《中国药房》2024年24期
P. 98

·循证药学·


          抗结核药物性肝损伤发生率及其危险因素的Meta分析                                                           Δ


          谢琴琴    1, 2* ,季欢欢 ,龚美玲 ,贾运涛 (1.重庆医科大学药学院,重庆 400016;2.重庆医科大学附属儿童医
                                              2 #
                            2
                                    1, 2
          院药学部/国家儿童健康与疾病临床医学研究中心/儿童发育疾病研究教育部重点实验室/儿童发育重大疾病国
          家国际科技合作基地/儿童感染与免疫罕见病重庆市重点实验室,重庆 400014)

          中图分类号  R978.3;R969.3      文献标志码  A      文章编号  1001-0408(2024)24-3052-07
          DOI  10.6039/j.issn.1001-0408.2024.24.15

          摘   要  目的  系统评价抗结核药物性肝损伤(ATB-DILI)发生率及其危险因素。方法  检索 PubMed、Embase、the Cochrane
          Library、Web of Science、中国知网、维普网、万方数据、中国生物医学文献数据库,收集抗结核药物治疗结核后发生ATB-DILI及其
          危险因素分析的病例对照研究和队列研究,检索时限为建库至 2024 年 5 月 31 日。筛选文献、提取数据,评价文献质量后,采用
          Stata 17.0 软件和 RevMan 5.3 软件进行 Meta 分析。结果  共纳入 26 篇文献,涉及 38 971 例患者,其中 ATB-DILI 患者为 4 106 例。
          Meta分析结果显示,ATB-DILI发生率为12.94%[95%CI(10.82%,15.06%),P<0.001];亚组分析显示,在队列研究、中国研究、儿童
          患者中ATB-DILI发生率更高(P<0.001)。年龄≥60岁、体重指数异常、嗜酒、吸烟、肝病史、乙肝表面抗原阳性、肺外结核、营养不
          良、低蛋白血症、心血管疾病、糖尿病、系统性红斑狼疮、未预防性使用保肝药、丙氨酸转氨酶基线水平高对发生ATB-DILI均有显
          著影响(P<0.05)。敏感性分析和发表偏倚分析结果显示,本研究所得结果稳健可靠。结论  结核患者使用抗结核药物治疗后的
          ATB-DILI发生率为12.94%;年龄≥60岁、体重指数异常、嗜酒、吸烟、肝病史、乙肝表面抗原阳性、肺外结核、营养不良、低蛋白血
          症、心血管疾病、糖尿病、系统性红斑狼疮、未预防性使用保肝药、丙氨酸转氨酶基线水平高均是发生ATB-DILI的危险因素。
          关键词  抗结核药;药物性肝损伤;发生率;危险因素;Meta分析

          Meta-analysis of the incidence and risk factors of anti-tuberculosis drug-induced liver injury
                                                                  2
                                                    1, 2
                     1, 2
          XIE Qinqin ,JI Huanhuan ,GONG Meiling ,JIA Yuntao (1.  School  of  Pharmacy,  Chongqing  Medical
                                    2
          University,  Chongqing  400016,  China;2.  Dept.  of  Pharmacy,  Children’s  Hospital  of  Chongqing  Medical
          University/National  Clinical  Research  Center  for  Child  Health  and  Disorders/Ministry  of  Education  Key
          Laboratory of Child Development and Disorders/China International Science and Technology Cooperation Base of
          Child  Development  and  Critical  Disorders/Chongqing  Key  Laboratory  of  Child  Rare  Diseases  in  Infection  and
          Immunity, Chongqing 400014, China)

          ABSTRACT    OBJECTIVE  To  systematically  evaluate  the  incidence  of  anti-tuberculosis  drug-induced  liver  injury (ATB-DILI)
          and  its  risk  factors.  METHODS  PubMed,  Embase,  the  Cochrane  Library,  Web  of  Science,  China  Knowledge  Network,  VIP,
          Wanfang  data  and  China  Biomedical  Literature  Database  were  searched  to  collect  cohort  studies  and  case-control  studies  on  the
          incidence and risk factors of ATB-DILI from the establishment of the database to 31 May 2024. After screening literature, extracting
          data and evaluating the quality of literature, meta-analysis was performed using Stata 17.0 and RevMan 5.3 software. RESULTS A
          total  of  26  literature  involving  38  971  patients  were  included,  of  which  4  106  patients  suffered  from  ATB-DILI.  Meta-analysis
          showed  that  the  incidence  of  ATB-DILI  was  12.94%  [95%CI (10.82%,15.06%),  P<0.001];  subgroup  analysis  showed  that  the
          incidence of ATB-DILI  in  cohort  studies,  Chinese  studies  and  pediatric patients was  higher (P<0.001). Age≥60  years,  abnormal
          body  mass  index,  alcoholism,  smoking,  history  of  liver  disease,  hepatitis  B  surface  antigen  positivity,  extrapulmonary
          tuberculosis,  malnutrition,  hypoproteinemia,  cardiovascular  disease,  diabetes  mellitus,  systemic  lupus  erythematosus,  no
          prophylactic use of hepatoprotective drugs, and high baseline alanine transaminase levels were risk factors for developing ATB-DILI
         (P<0.05).  Sensitivity  analysis  and  publication  bias  analysis  showed  that  the  results  obtained  in  this  study  were  relatively  robust.
          CONCLUSIONS  The  incidence  of  ATB-DILI  in  tuberculosis  patients  is  12.94%.  Age≥60  years,  abnormal  body  mass  index,
          alcoholism,  smoking,  history  of  liver  disease,  hepatitis  B  surface  antigen  positivity,  extrapulmonary  tuberculosis,  malnutrition,
                                                              hypoproteinaemia,  cardiovascular  disease,  diabetes  mellitus,
              Δ 基金项目 重庆市科卫联合医学科研项目(No.2022ZDXM020);
                                                              systemic  lupus  erythematosus,  non-prophylactic  use  of
          重庆医科大学未来医学青年创新团队发展支持计划项目(No.W0081);
                                                              hepatoprotective  medications,  and  high  baseline  levels  of
          重庆医科大学研究生智慧医学专项研发计划(No.YJSZHYX202209)
             *第一作者 硕士研究生。研究方向:临床药学、药物警戒。                      alanine  transaminase  are  the  risk  factors  for  developing  ATB-
          E-mail:2022120924@stu.cqmu.edu.cn                   DILI.
              # 通信作者 主任药师,硕士。研究方向:临床药学、药物警戒。                  KEYWORDS    antitubercular  agents;  drug-induced  liver
          E-mail:jiayuntaomail@hospital.cqmu.edu.cn           injury; incidence; risk factors; meta-analysis


          · 3052 ·    China Pharmacy  2024 Vol. 35  No. 24                            中国药房  2024年第35卷第24期
   93   94   95   96   97   98   99   100   101   102   103